DNA X, Inc.
For the period ended Jun 30, 2026. Filed Aug 19, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 19, 2026
SONM$2.22+4.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
CONSOLIDATED BALANCE SHEETS
| June 30, 2026 | December 31, 2025 | |
|---|---|---|
| (Unaudited) | ||
| Assets | ||
| Cash and cash equivalents | $900 | $1,303 |
| Receivable for cash held back from the asset sale | 1,248 | — |
| Receivable, related party | 15 | — |
| Prepaid expenses and other current assets | 759 | 676 |
| Current assets held for sale | — | 26,930 |
| Total Current assets | 2,922 | 28,909 |
| Investment in DNA X LLC under equity method | — | 1,242 |
| Identifiable intangible assets | 1,379 | — |
| Deferred tax assets | — | 1,441 |
| Other assets | 216 | 274 |
| Non-current assets held for sale | — | 12,032 |
| Total assets | $4,517 | $43,898 |
| Liabilities and stockholders’ deficit | ||
| Accounts payable | 683 | 4,030 |
| Accrued liabilities | 960 | 704 |
| Promissory note, net from related party | 2,400 | 1,035 |
| Promissory notes, net | — | 4,030 |
| Derivative liability | 797 | 171 |
| Income tax payable | 309 | 2,598 |
| Current liabilities held for sale | — | 38,057 |
| Total current liabilities | 5,149 | 50,625 |
| Deferred tax liability | 600 | — |
| Total liabilities | 5,749 | 50,625 |
| Commitments and contingencies (Note 10) | — | — |
| Redeemable common stock; $0.001 par value; 223,201 shares issued and outstanding; redemption value $1,228 as of December 31, 2025 (Note 7) | — | 1,228 |
| Stockholders’ deficit | ||
| Common stock, $0.001 par value per share; 1,000,000,000 shares authorized: and 1,488,268 and 1,265,067 shares issued and outstanding at June 30, 2026 and December 31, 2025 respectively* | 1 | 1 |
| Preferred stock, $0.001 par value per share, 5,000,000 shares authorized: and no shares issued and outstanding at June 30, 2026 and December 31, 2025 | — | — |
| Additional paid-in capital* | 297,674 | 296,309 |
| Accumulated deficit | (298,907) | (304,265) |
| Total stockholders’ deficit | (1,232) | (7,955) |
| Total liabilities, redeemable common stock, and stockholders’ deficit | $4,517 | $43,898 |
| * | Adjusted retroactively to reflect the 1-for-18 reverse stock split that became effective on October 28, 2025, see Note 1. |
|---|
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.